Why the study?
Does captopril 37.5-112.5 mg daily cause side effects and metabolic abnormalities in patients with mild to moderate essential hypertension?
Does captopril 37.5-112.5 mg daily cause side effects and metabolic abnormalities in patients with mild to moderate essential hypertension?
Captopril at 37.5-112.5 mg daily is effective and safe with minimal metabolic side effects for treating mild to moderate essential hypertension in patients without renal impairment.
Should not yet change practice in mild hypertension; leaves open need for randomized confirmation of metabolic safety.
Captopril Research Group of Japan made an evaluation of clinical usefulness of captopril in the treatment of mild to moderate essential hypertension. A relatively low frequency of side effects manifested as clinical symptoms was observed when the daily dose of captopril used was 37.5-112.5 mg. Antihypertensive effect was well maintained in this dose range. Follow-up surveillance of captopril also confirmed this. Abnormalities in blood chemistry were also found to be very less frequent. Untoward metabolic effects of ACE inhibitors such as alteration of serum electrolytes, lipid profiles or glucose metabolism were reported to be minimal or not actually observed. Side effects and untoward metabolic effects may appear more frequently when the same dose was given in patients with renal impairment. ACE inhibitors can be used as the first choice of drugs in the treatment of essential hypertension with no renal function impairment.
No takes yet. Share an insight, caveat, or question.
Omae et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: